1 |
Berezikov E (2011). Evolution of microRNA diversity and regulation in animals. Nat Rev Genet, 12, 846-60.
DOI
ScienceOn
|
2 |
Dip N, Reis ST, Timoszczuk LS, et al (2012). Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile. J Urol, 188, 1951-6.
DOI
ScienceOn
|
3 |
Esteller M (2011). Non-coding RNAs in human disease. Nat Rev Genet, 12, 861-74.
DOI
ScienceOn
|
4 |
Hanlon K, Rudin CE, Harries LW (2009). Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL). PLoS One, 4, e7169.
DOI
ScienceOn
|
5 |
Hu Z, Lin Y, Chen H, et al (2013). MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met. Biochem Biophys Res Commun, 435, 82-7.
DOI
ScienceOn
|
6 |
Jacobs BL, Lee CT, Montie JE (2010). Bladder cancer in 2010: how far have we come? CA Cancer J Clin, 60, 244-72.
DOI
|
7 |
Linsley PS, Schelter J, Burchard J, et al (2007). Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol, 27, 2240-52.
DOI
ScienceOn
|
8 |
Ma Q, Wang X, Li Z, et al (2013). microRNA-16 represses colorectal cancer cell growth in vitro by regulating the p53/survivin signaling pathway. Oncol Rep, 29, 1652-8.
|
9 |
Majid S, Dar AA, Saini S, et al (2012). MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1 in bladder cancer. PLoS One, 7, e46743.
DOI
|
10 |
Malmstrom PU, Loskog AS, Lindqvist CA, et al (2010). AdCD40L immunogene therapy for bladder carcinoma the first phase I/IIa trial. Clin Cancer Res, 16, 3279-87.
DOI
|
11 |
Neely LA, Rieger-Christ KM, Neto BS, et al (2010). A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol, 28, 39-48.
DOI
|
12 |
Noguchi S, Yasui Y, Iwasaki J, et al (2013) Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. Cancer Lett, 328, 353-61.
DOI
ScienceOn
|
13 |
O'Kelly F, Marignol L, Meunier A, et al (2012). MicroRNAs as putative mediators of treatment response in prostate cancer. Nat Rev Urol, 9, 397-407.
DOI
ScienceOn
|
14 |
Shimizu T, Suzuki H, Nojima M, et al (2013). Methylation of a Panel of MicroRNA Genes Is a Novel Biomarker for Detection of Bladder Cancer. Eur Urol, 63, 1091-100.
DOI
ScienceOn
|
15 |
Song T, Zhang X, Zhang L, et al (2013). miR-708 promotes the development of bladder carcinoma via direct repression of Caspase-2. J Cancer Res Clin Oncol, 139, 1189-98.
DOI
ScienceOn
|
16 |
Sun CY, She XM, Qin Y, et al (2013). miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis, 34, 426-35.
DOI
ScienceOn
|
17 |
Takeshita F, Patrawala L, Osaki M, et al (2010). Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther, 18, 181-7.
DOI
|
18 |
van Kouwenhove M, Kedde M, Agami R (2011). MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer, 11, 644-56.
DOI
ScienceOn
|
19 |
Voutsinas GE, Stravopodis DJ (2009). Molecular targeting and gene delivery in bladder cancer therapy. J Buon, 14, S69-78.
|
20 |
Vardouli L, Lindqvist C, Vlahou K, et al (2009). Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas. Cancer Gene Ther, 16, 848-60.
DOI
ScienceOn
|
21 |
Wang S, Xue S, Dai Y, et al (2012). Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer. Diagn Pathol, 7, 159.
DOI
|
22 |
Zhang X, Wan G, Mlotshwa S, et al (2010). Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res, 70, 7176-86.
DOI
|
23 |
Zhu DX, Miao KR, Fang C, et al (2011). Aberrant microRNA expression in Chinese patients with chronic lymphocytic leukemia. Leuk Res, 35, 730-4.
DOI
ScienceOn
|
24 |
Pasquinelli AE (2012). MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet, 13, 271-82.
|